Bullish Points: 1. NextCure is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunomedicines for cancer and immune-related diseases. 2. The company's product candidate NC410 is in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors. 3. NextCure's product candidate NC762 is in a Phase 1/2 clinical trial for patients with lung cancer, breast cancer, ovarian cancer, or potentially other tumor types. 4. Cash, cash equivalents, and marketable securities as of June 30, 2023, were $130.6 million. 5. Existing funds are expected to last until mid-2025. 6. Other income, net increased by $1.1 million for the three months ended June 30, 2023, and by $1.9 million for the six months ended June 30, 2023, due to higher interest income a
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
03-06
Annual Report
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]